{
    "nct_id": "NCT05242822",
    "official_title": "A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations",
    "inclusion_criteria": "* Provide written informed consent prior to initiation of any study-specific procedures\n* Advanced stage solid tumor\n* Known FGFR2 and/or FGFR3 gene alteration, as confirmed by previous genomic analysis of tumor tissue or ctDNA\n* Measurable or evaluable disease according to RECIST v1.1\n* ECOG performance status 0 or 1\n* Adequate organ function, as measured by laboratory values (criteria listed in protocol)\n* Able to swallow, retain, and absorb oral medications\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known clinically-active or clinically-progressive brain metastases from non-brain tumors\n* History and/or current evidence of abnormal calcium-phosphorous homeostasis, ectopic mineralization or calcification, or corneal or retinal disorder/keratopathy\n* GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease\n* Active, uncontrolled bacterial, fungal, or viral infection\n* Women who are lactating or breastfeeding, or pregnant",
    "miscellaneous_criteria": ""
}